Dr. Clauw has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Pfizer, Lilly, Forest, Cypress Biosciences, Pierre Fabre, UCB, and AstraZeneca.
The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity
Version of Record online: 23 FEB 2010
Copyright © 2010 by the American College of Rheumatology
Arthritis Care & Research
Volume 62, Issue 5, pages 600–610, May 2010
How to Cite
Wolfe, F., Clauw, D. J., Fitzcharles, M.-A., Goldenberg, D. L., Katz, R. S., Mease, P., Russell, A. S., Russell, I. J., Winfield, J. B. and Yunus, M. B. (2010), The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. Arthritis Care Res, 62: 600–610. doi: 10.1002/acr.20140
- Issue online: 29 APR 2010
- Version of Record online: 23 FEB 2010
- Accepted manuscript online: 23 FEB 2010 12:00AM EST
- Manuscript Accepted: 10 FEB 2010
- Manuscript Received: 24 AUG 2009
- Lilly Research Laboratories
Additional Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.